GlassScriptPhysician profile
Katherine Royals
NPI 1013357334
$5,842.13
in general payments reported to CMS, 2019-2025
35 companies · $1,218 in 2025
The $1,218 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $444 · 2021: $836 · 2022: $1,039 · 2023: $957 · 2024: $1,165 · 2025: $1,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,339.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $767.49 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $700.85 | 2020-2025 | Ubrelvy, Qulipta, Linzess |
| Pfizer INC. | $637.41 | 2019-2025 | |
| Novo Nordisk INC | $629.51 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $466.69 | 2020-2025 | Trintellix |
| Lilly USA, LLC | $376.65 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $305.05 | 2021-2025 | Xifaxan |
| Corium, LLC | $199.71 | 2022-2024 | Azstarys |
| Astrazeneca Pharmaceuticals LP | $190.80 | 2020-2025 | Farxiga, Lokelma |
| Exact Sciences Corporation | $162.35 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $154.77 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $131.56 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.39 | 2022-2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $101.57 | 2022 | |
| Tris Pharma INC | $101.53 | 2022-2024 | Dyanavel Xr |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $97.85 | 2019-2025 | Shingrix, Arexvy, Boostrix |
| Merck Sharp & Dohme LLC | $88.08 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.88 | 2025 | |
| Astellas Pharma US INC | $58.64 | 2025 | Veozah |
| Biohaven Pharmaceuticals, INC. | $58.51 | 2021 | |
| Axsome Therapeutics, INC. | $47.37 | 2025 | Auvelity |
| Dynavax Technologies Corporation | $44.40 | 2023-2025 | Heplisav-B |
| Amarin Pharma, INC. | $44.13 | 2021-2022 | |
| Gilead Sciences, INC. | $44.07 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $35.61 | 2022-2023 | Quviviq |
| Abbott Laboratories | $34.48 | 2024 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $31.89 | 2023-2024 | Voquezna |
| Dexcom, INC. | $26.92 | 2021-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $24.71 | 2024 | Intellis Adaptivestim |
| Lundbeck LLC | $21.83 | 2025 | Vyepti |
| Shield Therapeutics INC | $18.18 | 2023 | Accrufer |
| Impel Pharmaceuticals INC. | $17.22 | 2022 | |
| Currax Pharmaceuticals LLC | $16.50 | 2025 | Onzetra Xsail, Contrave |
| Daiichi Sankyo INC. | $14.96 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Royals listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.